Home
Resources
Diseases
Compendium
Training
Evaluation
The Tool
The Tutorial
SYSVAC
About
Registry
E-learning courses
News
Webinars
Network
Steering Committee
Vision and Mission
Map
Meetings
Partners
Join us
Home
Resources
Resources
Type of publications
Guidelines (30)
NITAG documentation (1591)
Reports (55)
SAGE documentation (222)
Scientific publications (112)
Systematic reviews (SYSVAC) (2750)
Regions
Africa (267)
Americas (762)
Eastern Mediterranean (48)
Europe (704)
South-East Asia (78)
Western Pacific (196)
Diseases
Chikungunya (9)
Cholera (33)
COVID-19 (1481)
Cytomegalovirus (1)
Dengue (39)
Diphtheria (79)
Ebola (16)
Escherichia coli (ETEC) (2)
Haemophilus influenzae type B (66)
Hepatitis A (63)
Hepatitis B (153)
Hepatitis C (4)
Hepatitis E (5)
Herpes simplex (1)
Herpes zoster (66)
HIV / AIDS (10)
Human papillomavirus (HPV) (472)
Influenza (573)
Japanese encephalitis (34)
Lyme disease, Borreliosis (1)
Malaria (27)
Measles (128)
Meningococcal disease (145)
Mpox (55)
Mumps (46)
Pertussis (104)
Pneumococcal disease (270)
Poliomyelitis (84)
Q fever (1)
Rabies (28)
Rotavirus (115)
RSV (Respiratory syncytial virus) (47)
Rubella (64)
Salmonella (2)
Shigella (1)
Smallpox (16)
Streptococcus group B (6)
Tetanus (59)
Tick-borne encephalitis (12)
Tuberculosis (73)
Typhoid (23)
Varicella (69)
Yellow fever (42)
Zika (1)
Show more
4760 results found
2025
∙
WHO
WHO position paper on herpes zoster vaccines
2025
∙
WHO
WHO position paper on Respiratory Syncytial Virus (RSV)
2025
∙
Haute Autorité de Santé
H5N1 zoonotic influenza in France
2025
∙
Haute Autorité de Santé
Seasonal flu vaccination for people aged 65 and over in France. Role of the Efluelda and Fluad vaccines
2025
∙
Haute Autorité de Santé
Papillomavirus vaccination in France: expansion of the catch-up vaccination cohort in men and women up to the age of 26
2025
∙
Folkhälsomyndigheten
Recommendations for COVID-19 vaccination from September 1 2025 in Sweden
2025
∙
NACI
Updated recommendations on measles post-exposure prophylaxis
2025
∙
Jefferson Jones
Proposed clinical considerations for clesrovimab
2025
∙
Danielle Moulia
Evidence to Recommendations Framework: Clesrovimab
2025
∙
Susan Hills
Clinical guidance for use of virus-like particle chikungunya vaccine in pregnant and breastfeeding women
Home
Resources
Diseases
Compendium
Training
Evaluation
SYSVAC
News
Webinars
Network
Sign in / Register